Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1467335 Tyramine Interaction Study
NCT03979820Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PXS-4728A in Nonalcoholic steatohepatitis (NASH) and diabetic retinopathy (DR) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Tyramine Sensitivity Factor. Started Jul 2019; status: terminated.
02
Drugs
PXS-4728A
03
Conditions
Nonalcoholic steatohepatitis (NASH)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT03979820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03979820.